Article: ACCUMETRICS' VERIFYNOW P2Y12 TEST PROVIDES PHYSICIANS WITH INFO.

MEDIA RELEASE PR35383

(Full text of statement. Contact details below.)

Accumetrics' VerifyNow(R) P2Y12 Test Provides Physicians With Information to Assess a Patient's Response to Newly-Approved Prasugrel (Effient(R))

SAN DIEGO, July 14 /PRNewswire-AsiaNet -- With the recent FDA approval of the new P2Y12 inhibitor, prasugrel (Effient), Accumetrics, Inc. announces that its VerifyNow P2Y12 Test is not only able to assess response to Plavix(R), but also its newly approved competitor, Effient. In obtaining a result from the VerifyNow System, physicians are provided objective information to determine the response of an individual patient to their ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!